Lithia Motors crushed Q2 EPS estimates with 24% profit growth, but a slight revenue miss and rising debt pressured shares.

Palantir's valuation multiples are extreme outliers, far exceeding industry benchmarks and not fully justified by its strong, ...

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...